Importer of Controlled Substances; Notice of Application; Stepan Company, 19015 [2013-07147]
Download as PDF
<![CDATA[
19015
Federal Register / Vol. 78, No. 60 / Thursday, March 28, 2013 / Notices
recommend that the Respondent’s DEA
Certificate of Registration, Number
BJ5128067, be revoked.5
DEPARTMENT OF JUSTICE
Dated: February 12, 2013.
Gail A. Randall,
Administrative Law Judge.
Importer of Controlled Substances;
Notice of Application; SA INTL GMBH
C/O., Sigma Aldrich Co. LLC
[FR Doc. 2013–07195 Filed 3–27–13; 8:45 am]
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on February 1, 2013, SA INTL
GMBH C/O., Sigma Aldrich Co. LLC.,
3500 Dekalb Street, St. Louis, Missouri
63118, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the following basic classes of controlled
substances:
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application; Stepan
Company
Drug Enforcement Administration
Drug
This is notice that on February 6,
2013, Stepan Company, Natural
Products Department, 100 W. Hunter
Avenue, Maywood, New Jersey 07607,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
Coca Leaves (9040), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to
manufacture bulk controlled substance
for distribution to its customer.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
As noted in a previous notice
published in the Federal Register on
September 23, 1975, 40 FR 43745, all
applicants for registration to import a
basic class of any controlled substance
in schedules I or II are, and will
continue to be, required to demonstrate
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration, that the
requirements for such registration
pursuant to 21 U.S.C. 958(a); 21 U.S.C.
823(a); and 21 CFR 1301.34(b), (c), (d),
(e), and (f) are satisfied.
Dated: March 19, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
mstockstill on DSK4VPTVN1PROD with NOTICES
[FR Doc. 2013–07147 Filed 3–27–13; 8:45 am]
BILLING CODE 4410–09–P
5 The sole basis of my recommendation is the loss
of Respondent’s state licensure. I make no findings
or conclusions concerning the other allegations
asserted in the Order to Show Cause.
VerDate Mar<15>2010
20:20 Mar 27, 2013
Jkt 229001
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Aminorex (1585) ...........................
Gamma
Hydroxybutyric
Acid
(2010).
Methaqualone (2565) ...................
Alpha-ethyltryptamine (7249) .......
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
4-Methoxyamphetamine (7411) ...
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
N-Benzylpiperazine (7493) ...........
Heroin (9200) ...............................
Normorphine (9313) .....................
Etonitazene (9624) .......................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Glutethimide (2550) ......................
Nabilone (7379) ............................
Phencyclidine (7471) ....................
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
Cocaine (9041) .............................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium, powdered (9639) .............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import the
listed controlled substances for sale to
research facilities for drug testing and
analysis.
In reference to drug codes 7360 and
7370, the company plans to import a
synthetic cannabidiol and a synthetic
Tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR
3417(2007).
In regard to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 29, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import basic classes of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 78, Number 60 (Thursday, March 28, 2013)]
[Notices]
[Page 19015]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07147]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application; Stepan
Company
This is notice that on February 6, 2013, Stepan Company, Natural
Products Department, 100 W. Hunter Avenue, Maywood, New Jersey 07607,
made application by renewal to the Drug Enforcement Administration
(DEA) for registration as an importer of Coca Leaves (9040), a basic
class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance to
manufacture bulk controlled substance for distribution to its customer.
Comments and requests for hearings on applications to import
narcotic raw material are not appropriate. 72 FR 3417 (2007).
As noted in a previous notice published in the Federal Register on
September 23, 1975, 40 FR 43745, all applicants for registration to
import a basic class of any controlled substance in schedules I or II
are, and will continue to be, required to demonstrate to the Deputy
Assistant Administrator, Office of Diversion Control, Drug Enforcement
Administration, that the requirements for such registration pursuant to
21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d),
(e), and (f) are satisfied.
Dated: March 19, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-07147 Filed 3-27-13; 8:45 am]
BILLING CODE 4410-09-P
